Issued: 22 February 2019, London UK - LSE Announcement
GSK response to SFO Statement
In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
GSK enquiries: |
|
|
|
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
Tim Foley |
+44 (0) 20 8047 5502 |
(London) |
Analyst/Investor enquiries: |
Sarah Elton-Farr |
+44 (0) 208 047 5194 |
(London) |
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
Cautionary statements regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. |
Registered in England & Wales: No. 3888792 |
|
|
|
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |
|
